Upgrade to SI Premium - Free Trial

Minerva Neurosciences (NERV)

4.67 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/4/26)

Latest Headlines

Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Ahlholm Frederick W June 5, 2026 6:00 PM - SEC Filing Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Luthringer Remy June 5, 2026 6:00 PM - SEC Filing Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Laghrissi-Thode Fouzia June 5, 2026 6:00 PM - SEC Filing Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Kaul Inderjit June 5, 2026 6:00 PM - SEC Filing Form 4 Minerva Neurosciences, For: Jun 03 Filed by: Kupfer David June 5, 2026 6:00 PM - SEC Filing Form 4 Minerva Neurosciences, For: Jun 03 Filed by: HASLER HANS PETER June 5, 2026 6:00 PM - SEC Filing Form 4 Minerva Neurosciences, For: Jun 03 Filed by: VAN HEEK G JAN June 5, 2026 6:00 PM - SEC Filing Form 8-K Minerva Neurosciences, For: Jun 03 June 4, 2026 4:06 PM - SEC Filing Minerva Neurosciences forms scientific advisory board June 1, 2026 4:05 PM - StreetInsider Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs June 1, 2026 4:05 PM - StreetInsider Form 8-K Minerva Neurosciences, For: May 27 May 27, 2026 4:18 PM - SEC Filing Form 424B5 Minerva Neurosciences, May 27, 2026 4:15 PM - SEC Filing Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference May 18, 2026 4:05 PM - StreetInsider Form SCHEDULE 13G Minerva Neurosciences, Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 11:44 AM - SEC Filing Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P. May 15, 2026 6:36 AM - SEC Filing Minerva Neurosciences (NERV) Misses Q1 EPS by 4c May 5, 2026 10:18 AM - StreetInsider Form 10-Q Minerva Neurosciences, For: Mar 31 May 5, 2026 8:31 AM - SEC Filing Form 8-K Minerva Neurosciences, For: May 05 May 5, 2026 8:09 AM - SEC Filing Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates May 5, 2026 8:00 AM - Globe NewsWire Form ARS Minerva Neurosciences, For: Dec 31 April 23, 2026 7:08 AM - SEC Filing Form DEFA14A Minerva Neurosciences, April 23, 2026 7:05 AM - SEC Filing Form DEF 14A Minerva Neurosciences, For: Jun 03 April 23, 2026 7:04 AM - SEC Filing Form 4 Minerva Neurosciences, For: Apr 21 Filed by: O'Connor James Joseph April 22, 2026 4:56 PM - SEC Filing Form 3 Minerva Neurosciences, For: Apr 21 Filed by: O'Connor James Joseph April 22, 2026 4:54 PM - SEC Filing Citizens Starts Minerva Neurosciences (NERV) at Market Outperform April 15, 2026 2:23 AM - StreetInsider Form PRE 14A Minerva Neurosciences, For: Jun 03 April 10, 2026 9:21 AM - SEC Filing Form 8-K Minerva Neurosciences, For: Apr 06 April 6, 2026 5:08 PM - SEC Filing Form 8-K Minerva Neurosciences, For: Mar 30 April 2, 2026 4:16 PM - SEC Filing Minerva Neurosciences names Jim O'Connor as chief business officer April 2, 2026 4:05 PM - StreetInsider Minerva Announces Leadership Transition April 2, 2026 4:05 PM - StreetInsider Form 4 Minerva Neurosciences, For: Mar 31 Filed by: Kaul Inderjit April 1, 2026 4:15 PM - SEC Filing Form 144 Minerva Neurosciences, Filed by: FEDERATED HERMES INSURANCE SERIES March 31, 2026 5:00 PM - SEC Filing Form 144 Minerva Neurosciences, Filed by: Federated Hermes Equity Funds March 31, 2026 4:58 PM - SEC Filing Form 144 Minerva Neurosciences, Filed by: Federated Hermes Equity Funds March 31, 2026 4:57 PM - SEC Filing Minerva starts phase 3 trial for schizophrenia drug roluperidone March 31, 2026 4:05 PM - StreetInsider Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia March 31, 2026 4:05 PM - StreetInsider Minerva Neurosciences presents safety data on roluperidone-olanzapine combo March 25, 2026 4:05 PM - StreetInsider Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 March 25, 2026 4:05 PM - StreetInsider Form EFFECT Minerva Neurosciences, March 20, 2026 6:07 AM - SEC Filing Full Article List